Medtronic invests $90M in medtech company behind one-of-a-kind TAVR tech
Medtronic has finalized a $90 million investment in Anteris Technologies, a Minnesota-based medtech company focused on advanced structural heart technologies.
Anteris is known for its biomimetic transcatheter aortic valve replacement (TAVR) valve, the DurAVR Transcatheter Heart Valve (THV) System. The DurAVR valve is made from a single piece of anti-calcification ADAPT tissue patented by Anteris. It was built to mimic the performance of a healthy aortic valve. The device is the first THV of its kind and has gained considerable attention as the TAVR market continues to grow.
Anteris first announced the potential of a strategic investment from Medtronic, one of the world’s leaders in TAVR technology, on Jan. 20. The move was closed immediately after Anteris completed a public offering of common stock. In total, the company raised a combined $320 million in gross proceeds that will go toward continuing research on the DurAVR THV system.
“This strategic investment, along with our underwritten offering of common stock, represent an important milestone for our company,” Wayne Paterson, vice chairman and CEO of Anteris, said in a statement. “It also provides strong validation of our program from the capital markets and a major strategic innovator. The investment is one aspect of a collaboration that may expand into other strategic areas in the future.”
“Our investment in differentiated innovation like the DurAVR THV technology—which has the potential to offer improved valve performance in a balloon-expandable platform—is core to our commitment to define and drive the future of TAVR, meeting the needs of more aortic stenosis patients and heart teams with a comprehensive portfolio,” added Jorie Soskin, vice president and general manager of Medtronic’s structural heart business.
Key research on the DurAVR THV system now underway
The DurAVR THV system has not yet been approved by the U.S. Food and Drug Administration (FDA). However, the FDA did approve PARADIGM, a global pivotal trial focused on the device’s safety and effectiveness, in November 2025. PARADIGM will enroll approximately 1,000 patients from throughout the United States, Europe and Canada.
Anteris did release data on 100 patients who received the DurAVR THV system at PCR London Valves in 2025. According to that early analysis, the valve was linked to positive 30-day clinical outcomes and no valve-related mortality. For the final 50 patients receiving the valve, the company added, the technical success rate was 100%.
In 2024, meanwhile, researchers presented one-year data on the world’s first patients to receive the DurAVR THV system at SCAI 2024 Scientific Sessions. The valve was successfully implanted in all 28 patients, and there were no signs of severe or even moderate aortic stenosis after 12 months.
Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.